ArticleFrontiers in oncology2025
Development and validation of a multimodal feature fusion-based model for predicting postoperative recurrence-free survival in locally advanced laryngeal squamous cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Given the high postoperative recurrence of locally advanced laryngeal squamous cell carcinoma (LSCC) and American Joint Committee on Cancer (AJCC) staging system prediction limitations, this study aims to construct and validate a postoperative recurrence-free survival (RFS) prediction model using multimodal feature fusion and explore data integration strategies to enhance prediction efficacy. Methods: Data from 278 patients diagnosed with locally advanced LSCC between 2013 and 2024 were collected retrospectively. These data were then separated into a training dataset (n = 196) and a validation dataset (n = 82), using a near 7:3 allocation strategy. By integrating clinicopathological features, preoperative blood markers, and enhanced computed tomography imaging data, we constructed clinicopathological (Clinic-score), radiomics (Rad-score), and two fusion models: feature-level (FF-Model) and decision-level (DF-Model). Model performance was evaluated using the concordance index, time-dependent area under the receiver operating characteristic curve, calibration curve, and decision curve analyses. Improvement in model discriminative ability was assessed using continuous net reclassification improvement (cNRI) and integrated discrimination improvement (IDI). Results: At 24.5 months median follow-up, 95 patients (34.2%) experienced recurrence. In the validation set, the DF-Model significantly outperformed the FF-Model, Rad-score and Clinic-score models, and AJCC stages. Additionally, the DF-Model demonstrated superior calibration and clinical utility, better prediction of 1-year, 3-year, and 5-year RFS through cNRI/IDI analysis, and excellent risk stratification across datasets, AJCC stages, and tumor locations. Conclusion: The multimodal prediction DF-Model effectively integrates multi-source heterogeneous information, significantly improving the prediction accuracy of postoperative RFS in locally advanced LSCC, outperforming the FF-Model, single-modal models, and AJCC staging system, and demonstrating its potential clinical translational value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.